2-(1-氨基环丁基)乙-1-醇 | 1132814-49-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-(1-氨基环丁基)乙-1-醇
• 英文名称: 2-(1-aminocyclobutyl)ethan-1-ol
• 英文别名: 1-amino-1-(2-hydroxyethyl)cyclobutane；2-[1-aminocyclobutyl]ethanol；2-(1-aminocyclobutyl)ethanol
• CAS: 1132814-49-3
• 化学式: C₆H₁₃NO
• mdl: MFCD19215486
• 分子量: 115.175
• InChiKey: AKJLCLKIEWILAH-UHFFFAOYSA-N

物化性质

• 沸点：
  187.0±13.0 °C(Predicted)
• 密度：
  1.027±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(1-氨基环丁基)乙-1-醇 在 硫酸 、 palladium 10% on activated carbon 、 氢气 、 sodium hydride 、 potassium nitrate 、 三乙胺 、 sodium hydroxide 作用下， 以 乙醇 、 二甲基亚砜 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 120.0 ℃ 、101.33 kPa 条件下， 反应 13.0h， 生成 9'-amino-10'-fluoro-2',3'-dihydro-8'-oxo-11'-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4'-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7'-carboxylc acid
  参考文献：
  名称：

  Quinolone derivatives containing strained spirocycle as orally active glycogen synthase kinase 3β (GSK-3β) inhibitors for type 2 diabetics

  摘要：

  The design, synthesis, and evaluation of 6-6-7 tricyclic quinolones containing the strained spirocycle moiety aiming at the GSK-3 beta inhibitor were described. Among the synthesized compounds, 44, having a cyclobutane ring on a spirocycle, showed excellent GSK-3b inhibitory activity in both cell-free and cell-based assays (IC50 = 36 nM, EC50 = 3.2 mu M, respectively). Additionally, 44 decreased the plasma glucose concentration dose-dependently after an oral glucose tolerance test in mice. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.12.046
• 作为产物：
  描述：

  ethyl 2-(1-hydroxycyclobutyl)acetate 在 lithium aluminium tetrahydride 、 硫酸 、 palladium 10% on activated carbon 、 氢气 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 20.0~80.0 ℃ 、500.01 kPa 条件下， 反应 10.0h， 生成 2-(1-氨基环丁基)乙-1-醇
  参考文献：
  名称：

  Quinolone derivatives containing strained spirocycle as orally active glycogen synthase kinase 3β (GSK-3β) inhibitors for type 2 diabetics

  摘要：

  The design, synthesis, and evaluation of 6-6-7 tricyclic quinolones containing the strained spirocycle moiety aiming at the GSK-3 beta inhibitor were described. Among the synthesized compounds, 44, having a cyclobutane ring on a spirocycle, showed excellent GSK-3b inhibitory activity in both cell-free and cell-based assays (IC50 = 36 nM, EC50 = 3.2 mu M, respectively). Additionally, 44 decreased the plasma glucose concentration dose-dependently after an oral glucose tolerance test in mice. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.12.046

文献信息

• [EN] SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS<br/>[FR] AMINOQUINOLONES SPIROCYCLIQUES UTILISÉES EN TANT QU'INHIBITEURS DE GSK-3
  申请人：ACTIVX BIOSCIENCES INC

  公开号：WO2009035684A1

  公开（公告）日：2009-03-19

  Provided herein are spirocyclic aminoquinolones of formula I and compositions containing the compounds. The compounds and compositions provided herein are useful in the prevention, amelioration or treatment of GSK- 3 inhibitors mediated diseases. In Formula (I): X1 is O or NR8; A is bond or substituted or unsubstituted C1-C2 alkylene, wherein the substituents when present are selected from one to four Q2 groups; where Q2 is alkyl or haloalkyl; p is 0 or 1; and q is an integer of 0 to 2.

  本文提供了化学式I的螺环氨基喹啉类化合物和含有这些化合物的组合物。本文提供的化合物和组合物可用于预防、改善或治疗GSK-3抑制剂介导的疾病。在化学式(I)中：X1为O或NR8；A为键或取代或未取代的C1-C2烷基，其中取代基在存在时来自于一个到四个Q2基团；其中Q2为烷基或卤代烷基；p为0或1；q为0到2的整数。
• Spirocyclic aminoquinolones as GSK-3 inhibitors
  申请人：Cociorva Oana

  公开号：US08476261B2

  公开（公告）日：2013-07-02

  Provided herein are spirocyclic aminoquinolones of formula I and compositions containing the compounds. The compounds and compositions provided herein are useful in the prevention, amelioration or treatment of GSK-3 inhibitors mediated diseases. In Formula (I): X1 is O or NR8; A is bond or substituted or unsubstituted C1-C2 alkylene, wherein the substituents when present are selected from one to four Q2 groups; where Q2 is alkyl or haloalkyl; p is 0 or 1; and q is an integer of 0 to 2.

  本文提供的是公式I的螺环氨基喹啉和含有该化合物的组合物。本文提供的化合物和组合物在预防、改善或治疗GSK-3抑制剂介导的疾病方面有用。在公式(I)中：X1为O或NR8；A为键或取代或未取代的C1-C2烷基，其中取代基在存在时从1到4个Q2基中选择；其中Q2为烷基或卤代烷基；p为0或1；q为0至2的整数。
• SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS
  申请人：KYORIN PHARMACEUTICALS CO., LTD.

  公开号：US20140005184A1

  公开（公告）日：2014-01-02

  Provided herein are spirocyclic aminoquinolones of formula I and compositions containing the compounds. The compounds and compositions provided herein are useful in the prevention, amelioration or treatment of GSK-3 inhibitors mediated diseases.

  本文提供的是公式I的螺环氨基喹啉和含有这些化合物的组合物。这些化合物和组合物对预防、改善或治疗GSK-3抑制剂介导的疾病是有用的。
• CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA
  申请人：PHENEX PHARMACEUTICALS AG

  公开号：US20150344423A1

  公开（公告）日：2015-12-03

  The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide containing cyclic compounds of Formula (1) to Formula (5) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.

  本发明提供了用于孤儿核受体RORy的调节剂，并通过向需要治疗RORy介导的疾病的人类或哺乳动物施用这些新型RORy调节剂来治疗这些疾病的方法。具体而言，本发明提供了公式（1）至公式（5）的含有羧酰胺的环状化合物及其对映体、二对映异构体、互变异构体、/V-氧化物、溶剂化物和药学上可接受的盐。
• HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES
  申请人：THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

  公开号：US20150224105A1

  公开（公告）日：2015-08-13

  The present invention is directed to triazolopyrimidine, phenylpyrimidine, pyridopyridazine, and pyridotriazine compounds which are microtubule-stabilizing compounds and their use in the treatment of neurodegenerative disorders, in particular, tauopathies, such as for example, Alzheimer's disease, frontotemporal lobar degeneration, Pick's disease, progressive supranuclear palsy (PSP), and corticobasal degeneration. In addition, the compounds of the invention may be useful for other diseases where tau pathology is a comorbidity or where microtubule function is compromised, for example, schizophrenia, Parkinson's disease (PD), PD with dementia, Lewy body disease with dementia, and amyotrophic lateral sclerosis.

  本发明涉及三唑并嘧啶、苯基嘧啶、吡啶并吡嗪和吡啶并三嗪类化合物，它们是微管稳定剂化合物，以及它们在治疗神经退行性疾病中的应用，特别是tau病理学，例如阿尔茨海默病、额颞叶变性、皮克氏病、进展性上皮核瘤和皮质基底节变性。此外，本发明中的化合物也可能对其他tau病理学是共病或微管功能受损的疾病有用，例如精神分裂症、帕金森病（PD）、带有痴呆的PD、带有痴呆的Lewy体病和肌萎缩侧索硬化症。